Triptan use in Italy: Insights from administrative databases

Da, Roberto; Nigro, Amaury José Teixeira; Terrazzino, Salvatore; Sances, Grazia; Viana, Michele; Tassorelli, Cristina; Nappi, Giuseppe; Cargnin, Sarah; Pisterna, Alessia; Traversa, Giuseppe; Genazzani, Armando A.

doi:10.1177/0333102414550419

Cited by 21 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Dutch study revealed that 60% of the overusers were in the fifth and sixth decade of life. 32,33 Another epidemiological study described the high prevalence of ergot users and overusers in an older population, 34 but in our study we only found a low prevalence of ergot overusers (2.9%). A prospective study showed that triptan overusers outnumbered ergot overusers in the MOH population, hence triptan was the most common drug that caused MOH.…”

Section: Discussioncontrasting

confidence: 66%

See 1 more Smart Citation

Headache Characteristics and Clinical Features of Elderly Migraine Patients

2017

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 66%

“…Two other epidemiological studies also reported that triptan overusers were older than non‐overusers. The Dutch study revealed that 60% of the overusers were in the fifth and sixth decade of life …”

Section: Discussionmentioning

confidence: 99%

Headache Characteristics and Clinical Features of Elderly Migraine Patients

2017

View full text Add to dashboard Cite

show abstract

“…Several studies showed that among recognized migraineurs few subjects are submitted to specific treatment [5]. In a recent investigation, only from 0.7 to 1.0 % of the analyzed population on migraine subjects used triptans [6], while in other studies the percentage varied between 3.0 and 19 % [7,8].…”

Section: Introductionmentioning

confidence: 91%

Triptan use among hospital workers affected by migraine

et al. 2015

View full text Add to dashboard Cite

Triptans represent the most specific and effective treatment for migraine attacks. Nevertheless, in clinical practice, they are often underused. Hospital workers, in particular physicians, are expected to be more aware of the correct use of specific drugs, especially for a very common disease such as migraine. Aim of this study was to evaluate whether different hospital workers affected by migraine are able to correctly manage the most suitable therapy for their migraine attacks. During a 1-year period, we submitted hospital employees to a structured interview with a questionnaire to investigate the presence of headache and its characteristics. In particular, in the subpopulation of subjects affected by migraine, we took information regarding their usual treatment for the control of attacks. The type of drug and the category of the working activity were synthesized as two different ordinal variables. Difference in the distribution of the different drug categories was evaluated with Chi squared test. Statistics was performed with SPSS 13.0 for Windows systems. We enrolled 1250 consecutive subjects: 20.3 % of the population (254 patients) was affected by migraine. Triptans use was significantly lower than that of non-steroidal anti-inflammatory drugs. The distribution of the use of the drugs was significantly different (p < 0.0001) at Chi squared test. Among migraineur physicians, only 10.7 % used triptans. Even in this subgroup, we observed a significant difference (p < 0.0001) in the distribution of the use of the drugs at Chi squared test. Our findings show a reduced use of triptans among hospital workers. These data reflect the unsatisfactory dissemination of knowledge regarding the correct management of migraine attacks and the advantages of treatment with triptans. An incorrect therapeutic approach to migraine contributes to the risk of the most important complications, such as drugs abuse or illness chronicization. These findings suggest that an insufficient awareness of migraine-related therapeutic options also involves hospital workers, including physicians.

show abstract

“…Furthermore, among the four provinces with a monthly quantity limit of 6 units, the prevalence of patients exceeding these limits differed considerably. In Saskatchewan, only 2.1% of patients 42 (12)(13)(14)(15)(16) 24 (12)(13)(14)(15)(16) †In accordance with institutional privacy policies, data suppressed to avoid residual disclosure of small cells. ‡P value for comparison of prevalence of triptan use between provinces <.001.…”

Section: Resultsmentioning

confidence: 99%